List view / Grid view
The British Pharmacopoeia (BP) is a collection of authoritative and publicly available quality standards for medicines, supported by guidance and additional value-adding information. First published in 1864, the BP has an illustrious history that has been built on quality and continually responds to the needs of stakeholders and users.
The first part of an in-depth article on Quality by Design (QbD), published in European Pharmaceutical Review in December 2016, focused on designing quality in to a pharmaceutical drug product by considering dosage form design, and understanding the importance of active pharmaceutical ingredients’ (APIs’) and excipients’ properties.
In the context of clinical trial data disclosure, since 2010 the regulatory impetus has shifted towards enhanced disclosure obligations, culminating in the publication of a ‘pro-active’ policy on the publication of clinical trial data for medicinal products for human use1 (Policy 0070) by the European Medicines Agency (EMA) in October…
15 February 2017 | By Nicolás Giménez Stamminger, Manager IT Advisory, KPMG Switzerland
KMPG’s Nicolás Giménez Stamminger explains why serialisation is the solution to counterfeit medicines and how to implement a cost-effective serialisation strategy…
13 February 2017 | By Dr Penny Owen, Life Sciences Hub Wales
From government regulation to European trade, Life Sciences Hub Wales chairperson, Dr Penny Owen, looks ahead to the unknown of a post-Brexit world...
10 February 2017 | By Niamh Marriott, Digital Editor
We caught up with Nexeon’s CEO, Will Rosellini, to talk about the Internet of Medical Things - the dangers, the benefits and what the future holds...
8 February 2017 | By Brian White and Paul Taylor, Healthcare Analysts, Cantor Fitzgerald Europe
Healthcare analysts predict another difficult year ahead for the pharmaceutical giant, after 2016 was beset with competitive and pricing pressures...
6 February 2017 | By Pasi Kemppainen, Executive Consultant, Pharma Serialisation and Traceability
Pharma serialisation and traceability expert, Pasi Kemppainen, gives us his insights on how to ensure a future-proof and cost-effective strategy
European Pharmaceutical Review has been keeping the industry informed for 21 years and continues to bring insights into current and emerging technologies, contributions from recognised figures in the life science community and of course, the latest and most up to date news. To celebrate our success, we will be counting down…
1 February 2017 | By Jurgi Camblong (CEO, Sophia Genetics)
Sophia Genetics co-founder and CEO, Jurgi Camblong, tackles issues of privacy and security for healthcare patient data...
20 January 2017 | By Stephen Klasko, President and CEO, Thomas Jefferson University and Jefferson Health; Editor-in-Chief, Healthcare Transformation
With Trump’s rule imminent, President and CEO of Thomas Jefferson University, Stephen Klasko, puts forth a manifesto for healthcare reform, disruption and change…
11 January 2017 | By Niamh Marriott, Digital Editor
From an orphan drug sales boom to uncharted political landscapes, the CPhI Worldwide expert panel predict pharma’s biggest opportunities and threats in 2017.
Read the free-to-view digital version of the latest issue of European Pharmaceutical Review...
In this supplement: Raman imaging evaluating counterfeit Cialis® tablets; analysis of capsule-based dry powder inhalers; Raman spectroscopy to authenticate medicines; Raman roundtable; as well as expert views...
13 December 2016 | By European Pharmaceutical Review
With the huge range of processes involved in drug discovery and manufacture, it's no wonder we had to create a separate magazine for this content – and as such we have a wide variety of applications...
